ReviewNature reviews. Urology2022
Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.
Review in Nature reviews. Urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 1 synthesis or guideline pooled it, 180 citations in OpenAlex.
- Comparative efficacy of hyperthermic chemotherapy and BCG instillation in non-muscle invasive bladder cancer: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial.Investigative and clinical urology · 2026Trial
- Monopolar versus bipolar transurethral resection of bladder Tumour: post-hoc analysis of a prospective trial.World journal of urology · 2024Trial
- Factors associated with help-seeking for urinary symptoms among Chinese patients with bladder cancer: A qualitative study.Asia-Pacific journal of oncology nursing · 2026Article
- Evaluation of thulium laser endoscopic en bloc resection versus conventional trans-urethral en bloc resection of primary non-muscle invasive bladder cancer: a randomized controlled trial.International urology and nephrology · 2026Article
- Fruit and vegetable consumption, dietary and plasma carotenoids and risks of recurrence and progression in patients with non-muscle-invasive bladder cancer.European journal of nutrition · 2026Article
- Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression.The Journal of biological chemistry · 2026Article
- Article
- A multi-modal approach for decision making in bladder cancer.Nature reviews. Urology · 2026Review
- CT-derived tumor extracellular volume fraction for predicting recurrence in non-muscle-invasive bladder cancer.Abdominal radiology (New York) · 2026Article
- Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer.Cell reports. Medicine · 2026Article
- Two-step enucleation combined with needle electrode: a modified TURBT technique to enhance detrusor muscle detection.International urology and nephrology · 2026Article
- Recurrence in the chemotherapy regimen of bladder carcinoma originates from quiescent epidermoid-like cells.Nature communications · 2026Article
- LncRNA HMGA2-AS1 promotes postoperative recurrence in non-muscle-invasive bladder cancer by sponging miR-367-3p to activate YAP1.World journal of surgical oncology · 2026Article
- Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer.Science advances · 2026Article
- Association ofInternational journal of molecular sciences · 2026Article
- Intravesical folate-conjugated hydroxyethyl starch micelles for pH-triggered co-delivery of epirubicin and TLR7 agonist toward synergistic chemoimmunotherapy of bladder cancer.Materials today. Bio · 2026Article
- Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: a retrospective single-center experience in China.Virchows Archiv : an international journal of pathology · 2026Article
- Systemic administration of liposomal trehalose dimycolate induces NK1.1⁺ cell mediated antitumor immunity in bladder cancer.BMC cancer · 2026Article
- Recurrence Rate After Post-Operative Two-Hour Continuous Bladder Irrigation for Primary Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.Journal of personalized medicine · 2026Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into the detrusor muscle layer. Transurethral resection of bladder tumour (TURBT) is a diagnostic and potentially curative procedure for NMIBC, but has some limitations, including difficulties in ascertaining complete tumour removal upon piecemeal resection and the possibility of tumour re-implantation after the procedure. The oncological control of NMIBC is far from satisfactory, with a 1-year recurrence rate of 15-61%, and a 5-year recurrence rate of 31-78%. Various recurrence mechanisms have been described for NMIBC, such as undetected tumours upon cystoscopy, incomplete resection during TURBT, tumour re-implantation after TURBT, drop metastasis from upper tract urothelial carcinoma and field change cancerization. Understanding the recurrence mechanisms from a clinical perspective has strong implications for the optimization of NMIBC oncological outcomes, as a cure for patients with NMIBC can only be achieved by tackling all possible recurrence mechanisms in a comprehensive manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.